MARCUS HORWITZ

Summary

Affiliation: University of California
Country: USA

Publications

  1. pmc Targeted intracellular delivery of antituberculosis drugs to Mycobacterium tuberculosis-infected macrophages via functionalized mesoporous silica nanoparticles
    Daniel L Clemens
    Division of Infectious Diseases, University of California, Los Angeles, California, USA
    Antimicrob Agents Chemother 56:2535-45. 2012
  2. pmc Commonly administered BCG strains including an evolutionarily early strain and evolutionarily late strains of disparate genealogy induce comparable protective immunity against tuberculosis
    Marcus A Horwitz
    Division of Infectious Diseases, Department of Medicine, School of Medicine, University of California Los Angeles, Los Angeles, CA 90095, USA
    Vaccine 27:441-5. 2009
  3. ncbi request reprint A novel live recombinant mycobacterial vaccine against bovine tuberculosis more potent than BCG
    Marcus A Horwitz
    Department of Medicine, UCLA School of Medicine, University of California Los Angeles, CHS 37 121, 10833 Le Conte Avenue, Los Angeles, CA 90095 1688, USA
    Vaccine 24:1593-600. 2006
  4. ncbi request reprint Extraordinarily few organisms of a live recombinant BCG vaccine against tuberculosis induce maximal cell-mediated and protective immunity
    Marcus A Horwitz
    Department of Medicine, CHS 37 121, School of Medicine, University of California Los Angeles, 10833 Le Conte Ave, Los Angeles, CA 90095 1688, USA
    Vaccine 24:443-51. 2006
  5. pmc Enhancing the protective efficacy of Mycobacterium bovis BCG vaccination against tuberculosis by boosting with the Mycobacterium tuberculosis major secretory protein
    Marcus A Horwitz
    Dept of Medicine, CHS 37 121, School of Medicine, University of California, Los Angeles, 10833 Le Conte Ave, Los Angeles, CA 90095 1688, USA
    Infect Immun 73:4676-83. 2005
  6. ncbi request reprint Recombinant BCG expressing Mycobacterium tuberculosis major extracellular proteins
    Marcus A Horwitz
    Department of Medicine, School of Medicine, University of California Los Angeles, Los Angeles, CA 90095, USA
    Microbes Infect 7:947-54. 2005
  7. pmc A new vaccine against tuberculosis affords greater survival after challenge than the current vaccine in the guinea pig model of pulmonary tuberculosis
    Marcus A Horwitz
    Department of Medicine, School of Medicine, University of California Los Angeles, 10833 Le Conte Avenue, Los Angeles, CA 90095 1688
    Infect Immun 71:1672-9. 2003
  8. pmc The metabolic activity of Mycobacterium tuberculosis, assessed by use of a novel inducible GFP expression system, correlates with its capacity to inhibit phagosomal maturation and acidification in human macrophages
    Bai Yu Lee
    Division of Infectious Diseases, Department of Medicine, University of California Los Angeles, School of Medicine, Center for Health Sciences, Los Angeles, CA 90095 1688, USA
    Mol Microbiol 68:1047-60. 2008
  9. pmc Recombinant attenuated Listeria monocytogenes vaccine expressing Francisella tularensis IglC induces protection in mice against aerosolized Type A F. tularensis
    Qingmei Jia
    Division of Infectious Diseases, Department of Medicine, 37 121 Center for Health Sciences, School of Medicine, University of California Los Angeles, 10833 Le Conte Avenue, Los Angeles, CA 90095 1688, United States
    Vaccine 27:1216-29. 2009
  10. pmc A Replication-Limited Recombinant Mycobacterium bovis BCG vaccine against tuberculosis designed for human immunodeficiency virus-positive persons is safer and more efficacious than BCG
    Michael V Tullius
    Division of Infectious Diseases, Department of Medicine, School of Medicine, UCLA, Los Angeles, CA 90095 1688, USA
    Infect Immun 76:5200-14. 2008

Research Grants

  1. DEVELOPMENT AND TESTING OF NEW TUBERCULOSIS VACCINES
    MARCUS AARON HORWITZ; Fiscal Year: 2010
  2. DEVELOPMENT AND TESTING OF NEW TUBERCULOSIS VACCINES
    MARCUS HORWITZ; Fiscal Year: 2004
  3. Characterization of the Francisella tularensis phagosome
    MARCUS HORWITZ; Fiscal Year: 2003
  4. A TB Vaccine for AIDS Patients
    MARCUS AARON HORWITZ; Fiscal Year: 2010
  5. A TB Vaccine for AIDS Patients
    MARCUS HORWITZ; Fiscal Year: 2009
  6. Characterization of the M. tuberculosis phagosome
    MARCUS HORWITZ; Fiscal Year: 2007
  7. DEVELOPMENT AND TESTING OF NEW TUBERCULOSIS VACCINES
    MARCUS HORWITZ; Fiscal Year: 2007
  8. A TB Vaccine for AIDS Patients
    MARCUS HORWITZ; Fiscal Year: 2007
  9. Novel Antimicrobial Agents Against M. tuberculosis
    MARCUS HORWITZ; Fiscal Year: 2007
  10. M TUBERCULOSIS GLUTAMINE SYNTHETASE EXPORT & INHIBITION
    MARCUS HORWITZ; Fiscal Year: 2002

Collaborators

Detail Information

Publications26

  1. pmc Targeted intracellular delivery of antituberculosis drugs to Mycobacterium tuberculosis-infected macrophages via functionalized mesoporous silica nanoparticles
    Daniel L Clemens
    Division of Infectious Diseases, University of California, Los Angeles, California, USA
    Antimicrob Agents Chemother 56:2535-45. 2012
    ..These data demonstrate that MSNP provide a versatile platform that can be functionalized to optimize the loading and intracellular release of specific drugs for the treatment of tuberculosis...
  2. pmc Commonly administered BCG strains including an evolutionarily early strain and evolutionarily late strains of disparate genealogy induce comparable protective immunity against tuberculosis
    Marcus A Horwitz
    Division of Infectious Diseases, Department of Medicine, School of Medicine, University of California Los Angeles, Los Angeles, CA 90095, USA
    Vaccine 27:441-5. 2009
    ..0001 for differences in organ burden). Our study shows that late strains are not less potent than an early strain and argues against strain differences as a major factor in the variability of outcomes in BCG vaccine trials...
  3. ncbi request reprint A novel live recombinant mycobacterial vaccine against bovine tuberculosis more potent than BCG
    Marcus A Horwitz
    Department of Medicine, UCLA School of Medicine, University of California Los Angeles, CHS 37 121, 10833 Le Conte Avenue, Los Angeles, CA 90095 1688, USA
    Vaccine 24:1593-600. 2006
    ..As rBCG30 is significantly more potent than BCG against M. bovis challenge, it has potential as a vaccine against bovine tuberculosis in domesticated animals and in wild animal reservoirs...
  4. ncbi request reprint Extraordinarily few organisms of a live recombinant BCG vaccine against tuberculosis induce maximal cell-mediated and protective immunity
    Marcus A Horwitz
    Department of Medicine, CHS 37 121, School of Medicine, University of California Los Angeles, 10833 Le Conte Ave, Los Angeles, CA 90095 1688, USA
    Vaccine 24:443-51. 2006
    ..This study demonstrates that a very low inoculum of rBCG30 organisms has the capacity to induce strong protective immunity against tuberculosis and that rBCG30 is an extremely potent delivery system for mycobacterial antigens...
  5. pmc Enhancing the protective efficacy of Mycobacterium bovis BCG vaccination against tuberculosis by boosting with the Mycobacterium tuberculosis major secretory protein
    Marcus A Horwitz
    Dept of Medicine, CHS 37 121, School of Medicine, University of California, Los Angeles, 10833 Le Conte Ave, Los Angeles, CA 90095 1688, USA
    Infect Immun 73:4676-83. 2005
    ..03] and 0.6 +/- 0.1 log in the spleen [P = 0.002]). This study suggests that administering BCG-immunized people a booster vaccine comprising the 30-kDa protein may enhance their level of immunoprotection against tuberculosis...
  6. ncbi request reprint Recombinant BCG expressing Mycobacterium tuberculosis major extracellular proteins
    Marcus A Horwitz
    Department of Medicine, School of Medicine, University of California Los Angeles, Los Angeles, CA 90095, USA
    Microbes Infect 7:947-54. 2005
    ..rBCG30, which expresses and secretes large amounts of the M. tuberculosis 30 kDa major secretory protein, is currently in human clinical trials...
  7. pmc A new vaccine against tuberculosis affords greater survival after challenge than the current vaccine in the guinea pig model of pulmonary tuberculosis
    Marcus A Horwitz
    Department of Medicine, School of Medicine, University of California Los Angeles, 10833 Le Conte Avenue, Los Angeles, CA 90095 1688
    Infect Immun 71:1672-9. 2003
    ..The recombinant and parental strains are sensitive to the same antimycobacterial antibiotics. rBCG30, the first vaccine against TB more potent than nearly century-old BCG, is being readied for human clinical trials...
  8. pmc The metabolic activity of Mycobacterium tuberculosis, assessed by use of a novel inducible GFP expression system, correlates with its capacity to inhibit phagosomal maturation and acidification in human macrophages
    Bai Yu Lee
    Division of Infectious Diseases, Department of Medicine, University of California Los Angeles, School of Medicine, Center for Health Sciences, Los Angeles, CA 90095 1688, USA
    Mol Microbiol 68:1047-60. 2008
    ..These studies demonstrate that metabolic activity of M. tuberculosis correlates strongly with phagosomal maturation and that the inducible GFP expression system is useful for assessing metabolic activity of intracellular M. tuberculosis...
  9. pmc Recombinant attenuated Listeria monocytogenes vaccine expressing Francisella tularensis IglC induces protection in mice against aerosolized Type A F. tularensis
    Qingmei Jia
    Division of Infectious Diseases, Department of Medicine, 37 121 Center for Health Sciences, School of Medicine, University of California Los Angeles, 10833 Le Conte Avenue, Los Angeles, CA 90095 1688, United States
    Vaccine 27:1216-29. 2009
    ..tularensis LVS administered by the intranasal route, a route chosen to mimic airborne infection, and, most importantly, against aerosol challenge with the highly virulent Type A F. tularensis SchuS4 strain...
  10. pmc A Replication-Limited Recombinant Mycobacterium bovis BCG vaccine against tuberculosis designed for human immunodeficiency virus-positive persons is safer and more efficacious than BCG
    Michael V Tullius
    Division of Infectious Diseases, Department of Medicine, School of Medicine, UCLA, Los Angeles, CA 90095 1688, USA
    Infect Immun 76:5200-14. 2008
    ....
  11. pmc Inhibition of Mycobacterium tuberculosis glutamine synthetase as a novel antibiotic strategy against tuberculosis: demonstration of efficacy in vivo
    Günter Harth
    Department of Medicine, School of Medicine, University of California, Los Angeles, California 90095 1688, USA
    Infect Immun 71:456-64. 2003
    ..tuberculosis GS is a feasible therapeutic strategy against this pathogen and supports the concept that M. tuberculosis enzymes involved in cell wall biosynthesis, including major secretory proteins, have potential as antibiotic targets...
  12. pmc Glutamine synthetase GlnA1 is essential for growth of Mycobacterium tuberculosis in human THP-1 macrophages and guinea pigs
    Michael V Tullius
    Division of Infectious Diseases, Department of Medicine, School of Medicine, University of California Los Angeles, Los Angeles, California 90095 1688, USA
    Infect Immun 71:3927-36. 2003
    ..This strain was virulent in guinea pigs, although somewhat less so than the wild-type. These studies demonstrate that glnA1 is essential for M. tuberculosis virulence...
  13. pmc Francisella tularensis phagosomal escape does not require acidification of the phagosome
    Daniel L Clemens
    Division of Infectious Diseases, Department of Medicine, UCLA School of Medicine, CHS 37 121, 10833 LeConte Avenue, Los Angeles, CA 90095 1688, USA
    Infect Immun 77:1757-73. 2009
    ..tularensis strain Schu S4 and a recent clinical isolate) or by "F. tularensis subsp. novicida," indicating that F. tularensis disrupts its phagosomal membrane by a mechanism that does not require acidification...
  14. pmc The Mycobacterium bovis bacille Calmette-Guerin phagosome proteome
    Bai Yu Lee
    Division of Infectious Diseases, Department of Medicine, Center for Health Sciences, University of California Los Angeles School of Medicine, Los Angeles, California 90095 1688, USA
    Mol Cell Proteomics 9:32-53. 2010
    ..Our phagosome purification procedure and initial proteomics analyses set the stage for a quantitative comparative analysis of mycobacterial and latex bead phagosome proteomes...
  15. pmc A Francisella tularensis live vaccine strain (LVS) mutant with a deletion in capB, encoding a putative capsular biosynthesis protein, is significantly more attenuated than LVS yet induces potent protective immunity in mice against F. tularensis challenge
    Qingmei Jia
    Division of Infectious Diseases, Department of Medicine, School of Medicine, University of California Los Angeles, Los Angeles, CA 90095 1688, USA
    Infect Immun 78:4341-55. 2010
    ..n. immunization). These results show that LVS ΔcapB is significantly safer than LVS and yet provides potent protective immunity against virulent F. tularensis SchuS4 challenge...
  16. ncbi request reprint Uptake and intracellular fate of Francisella tularensis in human macrophages
    Daniel L Clemens
    Department of Medicine, Division of Infectious Diseases, University of California, 37 121 CHS, 10833 Le Conte Avenue, Los Angeles, CA 90095, USA
    Ann N Y Acad Sci 1105:160-86. 2007
    ..Further research is needed to determine the mechanisms underlying looping phagocytosis, and the maturational arrest, fibrillar coat formation, and disruption of the phagosome...
  17. pmc Identification, recombinant expression, immunolocalization in macrophages, and T-cell responsiveness of the major extracellular proteins of Francisella tularensis
    Bai Yu Lee
    Division of Infectious Diseases, 37 121 Center for the Health Sciences, University of California, Los Angeles, 10833 Le Conte Avenue, Los Angeles, CA 90095 1688, USA
    Infect Immun 74:4002-13. 2006
    ..Finally, we expressed the major culture filtrate proteins that are promising vaccine candidates in Escherichia coli at high levels in soluble form to facilitate study of their immunobiology and potential role in vaccines...
  18. pmc Virulent and avirulent strains of Francisella tularensis prevent acidification and maturation of their phagosomes and escape into the cytoplasm in human macrophages
    Daniel L Clemens
    Division of Infectious Diseases, Department of Medicine, UCLA School of Medicine, Los Angeles, California 90095 1688, USA
    Infect Immun 72:3204-17. 2004
    ..The capacity of F. tularensis to alter the maturation of its phagosome and to enter the cytoplasm is likely an important element of its capacity to parasitize macrophages and has major implications for vaccine development...
  19. ncbi request reprint A two-plasmid system for stable, selective-pressure-independent expression of multiple extracellular proteins in mycobacteria
    Günter Harth
    Division of Infectious Diseases, Department of Medicine, 37 121 CHS, University of California Los Angeles, 10833 Le Conte Avenue, Los Angeles, CA 90095 1688, USA
    Microbiology 150:2143-51. 2004
    ..coli or between E. coli strains. The combination of two compatible plasmids in one BCG strain allows expression of recombinant mycobacterial proteins at different levels, a potentially important factor in optimizing vaccine potency...
  20. pmc The Mycobacterium tuberculosis phagosome in human macrophages is isolated from the host cell cytoplasm
    Daniel L Clemens
    Division of Infectious Diseases, Department of Medicine, UCLA School of Medicine, Center for Health Sciences, Los Angeles, California 90095, USA
    Infect Immun 70:5800-7. 2002
    ..Our study shows that M. tuberculosis resides in an isolated phagosome that is relatively impermeable to cytoplasmic constituents...
  21. pmc Francisella tularensis enters macrophages via a novel process involving pseudopod loops
    Daniel L Clemens
    Division of Infectious Diseases, Dept of Medicine, UCLA School of Medicine, CHS 37 121, 10833 LeConte Ave, Los Angeles, CA 90095 1688, USA
    Infect Immun 73:5892-902. 2005
    ..These findings have significant implications for understanding the intracellular biology and virulence of this extremely infectious pathogen...
  22. pmc Targeting the Mycobacterium tuberculosis 30/32-kDa mycolyl transferase complex as a therapeutic strategy against tuberculosis: Proof of principle by using antisense technology
    Günter Harth
    Division of Infectious Diseases, Department of Medicine, 37 121 Center for Health Sciences, School of Medicine, University of California, 10833 Le Conte Avenue, Los Angeles 90095, USA
    Proc Natl Acad Sci U S A 99:15614-9. 2002
    ..5 logs. This study shows that the three mycolyl transferases are highly promising targets for antituberculous therapy by using antisense or other antimicrobial technologies...
  23. pmc Hairpin extensions enhance the efficacy of mycolyl transferase-specific antisense oligonucleotides targeting Mycobacterium tuberculosis
    Günter Harth
    Division of Infectious Diseases, Department of Medicine, 37 121 Center for Health Sciences, School of Medicine, University of California Los Angeles, 10833 Le Conte Avenue, Los Angeles, CA 90095 1688, USA
    Proc Natl Acad Sci U S A 104:7199-204. 2007
    ..This study demonstrates that 5'- and 3'-HPS-ODNs are highly efficacious against M. tuberculosis and supports the further development of antisense technology as a therapeutic modality against tuberculosis...
  24. ncbi request reprint Thiol antioxidants inhibit the adjuvant effects of aerosolized diesel exhaust particles in a murine model for ovalbumin sensitization
    Michael J Whitekus
    Department of Pathology and Laboratory Medicine and Jonsson Comprehensive Cancer Center, University of California School of Medicine, 10833 Le Conte Avenue, Los Angeles, CA 90095, USA
    J Immunol 168:2560-7. 2002
    ..Antioxidant treatment strategies may therefore serve to alleviate allergic inflammation and may provide a rational basis for treating the contribution of particulate matter to asthmatic disease...
  25. pmc Bucillamine, a thiol antioxidant, prevents transplantation-associated reperfusion injury
    Farin Amersi
    The Dumont University of California, Los Angeles Transplant Center, Division of Liver and Pancreas Transplantation, Department of Surgery, Los Angeles, CA 90095, USA
    Proc Natl Acad Sci U S A 99:8915-20. 2002
    ..This study demonstrates the potential utility of bucillamine or other cysteine-derived thiol donors for improving outcomes in organ transplantation and other clinical settings involving I/R injury...
  26. ncbi request reprint All four Mycobacterium tuberculosis glnA genes encode glutamine synthetase activities but only GlnA1 is abundantly expressed and essential for bacterial homeostasis
    Günter Harth
    Division of Infectious Diseases, Department of Medicine, School of Medicine, 37 121 CHS, University of California, Los Angeles, Los Angeles, CA 90095 1688, USA
    Mol Microbiol 58:1157-72. 2005
    ..tuberculosis drugs...

Research Grants48

  1. DEVELOPMENT AND TESTING OF NEW TUBERCULOSIS VACCINES
    MARCUS AARON HORWITZ; Fiscal Year: 2010
    ..tuberculosis. Lay Summary: Tuberculosis is a major worldwide public health problem. This proposal seeks to develop a more potent vaccine with which to combat this disease. ..
  2. DEVELOPMENT AND TESTING OF NEW TUBERCULOSIS VACCINES
    MARCUS HORWITZ; Fiscal Year: 2004
    ..We seek to develop and test live recombinant vaccines including recombinant BCG expressing major M. tuberculosis extracellular and cell-associated proteins and new non-live particulate vaccines formulated as liposomes and microspheres. ..
  3. Characterization of the Francisella tularensis phagosome
    MARCUS HORWITZ; Fiscal Year: 2003
    ..tularensis subverts the host cell membrane trafficking pathways and attains an intracellular compartment that is hospitable for its survival and growth will help guide new strategies for the prevention and treatment of tularemia. ..
  4. A TB Vaccine for AIDS Patients
    MARCUS AARON HORWITZ; Fiscal Year: 2010
    ..Finally, we shall confirm the safety of the new recombinant vaccines in an immunocompromised animal host (SCID mouse model). ..
  5. A TB Vaccine for AIDS Patients
    MARCUS HORWITZ; Fiscal Year: 2009
    ..Finally, we shall confirm the safety of the new recombinant vaccines in an immunocompromised animal host (SCID mouse model). ..
  6. Characterization of the M. tuberculosis phagosome
    MARCUS HORWITZ; Fiscal Year: 2007
    ..These experiments will advance our understanding of the cell biology and pathogenic mechanisms of M. tuberculosis and facilitate the development of new strategies to combat tuberculosis. ..
  7. DEVELOPMENT AND TESTING OF NEW TUBERCULOSIS VACCINES
    MARCUS HORWITZ; Fiscal Year: 2007
    ..tuberculosis. Lay Summary: Tuberculosis is a major worldwide public health problem. This proposal seeks to develop a more potent vaccine with which to combat this disease. ..
  8. A TB Vaccine for AIDS Patients
    MARCUS HORWITZ; Fiscal Year: 2007
    ..Finally, we shall confirm the safety of the new recombinant vaccines in an immunocompromised animal host (SCID mouse model). ..
  9. Novel Antimicrobial Agents Against M. tuberculosis
    MARCUS HORWITZ; Fiscal Year: 2007
    ..mammalian GS, and test the toxicity of the analogs in mice. 2) Test the novel MSO analogs for their capacity to inhibit M. tuberculosis growth in broth culture, in human macrophages, and in guinea pigs. ..
  10. M TUBERCULOSIS GLUTAMINE SYNTHETASE EXPORT & INHIBITION
    MARCUS HORWITZ; Fiscal Year: 2002
    ..tuberculosis glutamine synthetase, they hope to develop more active entities than the parent compound and thereby to develop a new antibiotic against M. tuberculosis. ..
  11. IMMUNOPROTECTIVE DETERMINANTS OF M TUBERCULOSIS IN AIDS
    MARCUS HORWITZ; Fiscal Year: 1999
    ..The goal of this project is to study systematically purified extracellular proteins of M. tuberculosis for their capacity to induce cell-mediated and protective immunity against tuberculosis in the guinea pig model. ..
  12. M TUBERCULOSIS PHAGOSOME
    MARCUS HORWITZ; Fiscal Year: 2002
    ..tuberculosis to survive and multiply within its host cells and should facilitate the development of new strategies for prevention and treatment of tuberculosis. ..
  13. MYCOBACTERIUM TUBERCULOSIS PHAGOSOME
    MARCUS HORWITZ; Fiscal Year: 1993
    ..tuberculosis infection. By providing new insights into the biology of M. tuberculosis, these studies will hopefully lead to new strategies for the prevention and treatment of tuberculosis...
  14. IMMUNOPROTECTIVE DETERMINANTS OF M TUBERCULOSIS IN AIDS
    MARCUS HORWITZ; Fiscal Year: 1993
    ..tuberculosis proteins that induce cell-mediated and protective immunity in guinea pigs; h) determine if immunoprotective proteins contain immunodominant regions across human MHC types...